Tempus support for Moderna-Merck personalized cancer vaccine commercialization

Mapped to your portfolio

Overview

Description Tempus is supporting Moderna and Merck’s potential commercialization of intismeran autogene through sequencing and sample logistics. Overview Tempus entered a multiyear collaboration with Moderna and Merck for intismeran autogene. The therapy is being evaluated with Keytruda in completely resected stage IIB-IV melanoma…

Possible scenarios

35%Momentum Extends+0.0%
30%Valuation Pullback-0.0%
20%Regulatory Clarity+0.0%

For information only. Not investment advice.

Stories in this saga

2 stories, 3 sources

Oct 7, 2026
Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug
Oct 11, 2026

Tempus support for Moderna-Merck personalized cancer vaccine commercialization

Mapped to your portfolio

Overview

Possible scenarios

Stories in this saga

Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug

Moderna Tops S&P 500 for 2026 With 663% Return

Portfolio

Possible scenarios

Mapped to your portfolio

Mapped to your portfolio

Overview

Possible scenarios

Keeping an eye on this saga?

Stories in this saga

Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug

Moderna Tops S&P 500 for 2026 With 663% Return

Portfolio

Possible scenarios

Mapped to your portfolio